Issue:
99
Page: 31-33
Water-Based Kava Extract for Generalized Anxiety Disorder Shows No Adverse Effects in Liver Function
by Heather S. Oliff, PhD
HerbalGram.
2013; American Botanical Council
Reviewed: Sarris J, Stough C,
Teschke R, Wahid ZT, Bousman CA, Murray G, Savage KM, Mouatt P, Ng C, and
Schweitzer I. Kava for the treatment of
generalized anxiety disorder RCT: analysis of adverse reactions, liver
function, addiction, and sexual effects. Phytother
Res. January 2013; [epub ahead of print]. doi: 10.1002/ptr.4916.
Empirical observations and clinical
trial evidence suggest that preparations made from the root of kava (Piper methysticum, Piperaceae) are
efficacious in the treatment of anxiety; however, cases of hepatotoxicity
associated with kava use have led to its withdrawal or restricted use in many
Western countries. Considering that kava has anxiolytic effects, questions
arise as to whether kava is addictive, has adverse sexual side effects, or has
withdrawal effects that might be similar to pharmaceutical anxiolytic drugs
such as the benzodiazepines (drugs with an anti-anxiety effect). Uncertainty
regarding the cause of the liver toxicity centers on poor-quality raw material,
plant cultivars, and extraction solvents. Hence the purpose of this randomized,
double-blind, placebo-controlled study was to evaluate adverse events (AEs),
withdrawal/addiction effects, and liver function effects associated with kava
use in patients with generalized anxiety disorder (GAD). Also, genetic
polymorphism (when more than one different phenotype exists in the same
species) of the liver enzyme
cytochrome P450 2D6 (CYP2D6), which metabolizes compounds in kava, was
evaluated to determine whether subjects who were poor or extensive metabolizers
have different AEs using water-extracted kava from noble cultivars (that is,
kava cultivars with higher levels of kavain and lower levels of
dihydromethysticin).1
Patients (n=58; aged 18-65 years)
with DSM-IV (Diagnostic and Statistical
Manual of Mental Disorders, 4th Edition) diagnosed with GAD were
recruited from the Greater Melbourne area in Victoria, Australia, via mass
media. Patients were excluded if they had any of the following conditions:
major depressive disorder or elevated depressive symptomatology (greater than
17 on the Montgomery-Asberg Depression Rating Scale); a DSM-IV diagnosis of a
psychotic or bipolar disorder; significant suicidal ideation in the previous
six months; current use of antidepressants, mood stabilizers, antipsychotics,
opioid analgesics, or St. John’s wort (Hypericum
perforatum, Clusiaceae); diagnosed hepatobiliary disease/inflammation;
substance abuse or dependency disorder in the previous six months; a previous
adverse reaction to kava or benzodiazepines; kava or benzodiazepine use in the
previous 12 months; or abnormal baseline liver function. The study began with a
one-week run-in phase to identify placebo responders. Any subject who showed a
50% improvement on the Hamilton Anxiety Scale (HAM-A) score during this placebo
phase was excluded from the study.
For six weeks, patients received
placebo or an aqueous kava extract with the equivalent of 120 mg of
kavalactones/day, which was titrated to 240 mg/day in patients showing no
response at three weeks. The kava was formulated from pressed, dried, aqueous
peeled rootstock of kava (Medi-Herb, Integria Healthcare; Eight Mile Plains,
Queensland, Australia). The kava extract was independently analyzed at Southern
Cross University at Lismore, Australia, and was determined to contain various
kavalactones: dihydrokavain (15.5 mg, 26%), kavain (12.5 mg, 21%),
dihydromethysticin (11 mg, 18%) methysticin (8.5 mg, 14%), yangonin (8 mg,
13%), and desmethoxygangonin (5mg, 8%); the alkaloid pipermethystine, which has
been implicated in some kava extracts associated with cases of liver
dysfunction, was not detected.
At weeks two
and seven, AEs were assessed via questionnaire, and blood was drawn for liver
function tests and to determine polymorphisms.
No significant
AEs were reported. One case of dermatitis and one case of minor stomach upset
were associated with kava intake. Withdrawal was assessed by treating all
patients with placebo for one week at study end. There was no significant
increase in AEs in either treatment group. Addiction was assessed by evaluating
the number of patients who said that they wanted an increase in dose. Both
treatment groups had the same number of patients who wanted to increase the
dosage. There were no significant differences from baseline in liver function
tests, and no patients developed clinical signs of hepatic abnormality.
However, gamma-glutamyl transpeptidase (GGT) showed a trend toward elevation in
kava-treated patients compared with those who took placebo at week seven
(P=0.08). This finding may be due to an outlier; one patient (an extensive
CYP2D6 metabolizer) had isolated increases in GGT and alanine aminotransferase
(ALT) that both returned to baseline levels after the study. However,
intermediate or extensive CYP2D6 metabolizer status had no significant impact
on the type or frequency of AEs or abnormal liver function tests. Kava did not
diminish sexual performance or enjoyment in men or women. However, there was a
trend for kava-treated men to have more difficulty reaching orgasm (P=0.067).
Kava-treated women had a significant increase in sex drive (P=0.04).
The authors
conclude that water-extracted kava from noble cultivars has no deleterious
effects on sexual function and pleasure, has no addictive qualities or
withdrawal issues, and is safe for patients with GAD when taken for six weeks.
The researchers also wrote that patients with GAD would require treatment for longer
than six weeks, so a larger, longer-term study is needed to confirm the
findings. Nonetheless, this study contributes to the growing body of evidence
that water-soluble, standardized formulations of kava from noble cultivars are
safe. The authors conclude that these data may assist in the reintroduction of
kava in restricted markets. This study uses a medicinal dose of kava, and the
results cannot be extrapolated to traditional recreational use with higher
doses of kavalactones.
—Heather S.
Oliff, PhD
Reference
1. Sarris J, Stough C,
Bousman CA, Wahid ZT, Murray G, Teschke R, Savage KM, Dowell A, Ng C,
Schweitzer I. Kava in the treatment of generalized anxiety disorder: a
double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol. 2013;33(5):1-6.
|